A feasibility study of neoadjuvant therapy with cisplatin, pemetrexed, and bevacizumab (Avastin&reg;) in patients with non-squamous non small cell lung cancer (NAVAL study) - A feasibility study of neoadjuvant therapy with cisplatin, pemetrexed, and bevacizumab (Avastin&reg;) in patients with non-squamous non small cell lung cancer (NAVAL study)

Thoracic Surgery, Hiroshima University Hospital0 个研究点目标入组 31 人开始时间: 2010年10月1日最近更新: 2023年10月17日

适应症

试验速览

See the attached file.

•1. Uncontrollable systemic disease (hyper tension or diabetes mellitus) 2. Current history of hemosputum or hemoptysis 3. Evidence of bleeding diathesis or coagulopathy 4. Cavity in lung tumor or great vessel involvement 5. Current or previous (within the last 1 year) history of cerebrovascular disease 6. Traumatic fracture of un recovery 7. History of active infection 8. Therapeutic anticoagulation; regular use of aspirin (>325 mg/day) 9. Severe GI disease 10. Current or previous (within the last 1 year) history of GI perforation or diverticultis 11. History of severe heart disease 12. Severe diarrhea 13. Severe drug allergy 14. Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 15. History of active double cancer 16. History of pregnancy or lactation 17. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator

发起方

Thoracic Surgery, Hiroshima University Hospital